A phase I study of asciminib in combination with dasatinib, prednisone, and blinatumomab for Ph-positive acute leukemia in adults.
Luskin M, Murakami M, Keating J, Wang E, McMasters M, Flamand Y, Winer E, Stahl M, Smith H, Jaeckle S, Weizer C, Fleming J, Saygin C, Stock W, DeAngelo D. A phase I study of asciminib in combination with dasatinib, prednisone, and blinatumomab for Ph-positive acute leukemia in adults. Journal Of Clinical Oncology 2025, 43: 6509-6509. DOI: 10.1200/jco.2025.43.16_suppl.6509.Peer-Reviewed Original ResearchPh+ acute lymphoblastic leukemiaAcute lymphoblastic leukemiaDose-limiting toxicityChronic myeloid leukemiaDose reductionAcute leukemiaPh-positive acute leukemiaTreatment of Ph+ acute lymphoblastic leukemiaDasatinib dose reductionT-cell engagersPhase I studyPhase 1 studyPh+ acute leukemiaSafety of dasatinibEfficacy of dasatinibExpansion cohortBlast crisisMedian WBCToxicity gradeMedian agePhysician's discretionPleural effusionMedian timeMyeloid leukemiaLymphoblastic leukemia
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply